2026 Annual Guidance

Dexcom is raising fiscal year 2026 guidance for Non-GAAP Operating Margin and Adjusted EBITDA Margin, and reiterating guidance for Revenue and Non-GAAP Gross Profit Margin at the following levels:

  • Revenue of $5.16 - $5.25 billion (approximately 11-13% growth)
  • Non-GAAP Gross Profit Margin of approximately 63-64%
  • Non-GAAP Operating Margin of approximately 23-23.5%
  • Adjusted EBITDA Margin of approximately 31-31.5%